| Document |
Document Title |
|
WO/2024/051641A1 |
The present invention provides an anti-EGFR and cMet bispecific chimeric antigen receptor and use thereof. Specifically, the present invention provides an immune cell expressing a first CAR and a second CAR, the first CAR targets a first...
|
|
WO/2024/054644A2 |
Featured are compositions, methods, and apparatuses for biosynthetic organs, or organoids, that replicate tissues of the human female reproductive system (e.g., ovarian or uterine tissues). In particular, the disclosure features methods ...
|
|
WO/2024/054414A1 |
Described herein is a low perfusion rate cell culture method for producing recombinant proteins.
|
|
WO/2024/053684A1 |
[Problem] To provide feeder cells for bidimensional culturing for maintenance or proliferation of cells and a method for producing feeder cells, the feeder cells being for cells for which maintenance and proliferation by bidimensional cu...
|
|
WO/2024/053985A1 |
The present invention relates to a composition for cryoprotection of exosomes, the composition including a biocompatible polymer including a network structure. By using the composition for cryoprotection of exosomes of the present invent...
|
|
WO/2024/050859A1 |
The present invention relates to the technical field of animal cell line models. Disclosed are a human breast malignant phyllodes tumor cell strain and a progeny cell line and use thereof. The cell line is named Human Breast Malignant Ph...
|
|
WO/2024/051383A1 |
Provided are an anti-Trop2 antibody, a conjugate comprising said antibody, and a use thereof. Specifically, provided are an anti-Trop2 single-domain antibody, a long-acting anti-Trop2 antibody formed from connecting, in tandem, an anti-T...
|
|
WO/2024/051106A1 |
A preparation and use of an anti-IL4i1 nano antibody. The anti-IL4i1 nano antibody has three unique complementarity-determining regions CDR1, CDR2, and CDR3, and nine sequences of the anti-IL4i1 nano antibody are selected in total. Furth...
|
|
WO/2024/052906A1 |
Disclosed herein are micropatterned surfaces, particularly in the shape of micro-brushes having a base and a plurality of elongated elements. The micropatterned surfaces suitably biofunctionalized are particularly useful for activation a...
|
|
WO/2024/054870A1 |
The use of IL-7Rαγc agonist peptides in cell manufacturing is disclosed. The IL-7Rαγc agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-7Rαγc agonist peptides, methods ...
|
|
WO/2024/053588A1 |
The block for preparing an observation section according to the present disclosure is equipped with a cell assembly, the cell assembly being in a three-dimensional shape and embedded, and a continuous or intermittent marker extending in ...
|
|
WO/2024/054518A1 |
Provided are systems and methods of enhancing tumor-reactive immune populations such as tumor infiltrating lymphocytes from patient-derived organoids. Also, provided herein are systems and methods of expanding and reprogramming tumor-rea...
|
|
WO/2024/052417A1 |
The invention lies in the field of material sciences and relates to a method of the kind that can be used, for example, in in-vivo reproduction and in healthcare, and to a device for realizing the controlled movement. The object of the p...
|
|
WO/2024/053957A1 |
The present invention provides a medium composition for direct differentiation of osteogenic cells and a method for direct differentiation of osteogenic cells, which induce osteogenic cells from somatic cells, the composition comprising,...
|
|
WO/2024/051752A1 |
Provided are bispecific and multi-specific antibodies that include an agonist anti-4-1BB single-domain antibody capable of effector function-mediated tumor inhibition. In addition, these agonist antibodies, in the absence of tumor antige...
|
|
WO/2024/050858A1 |
A malignant human breast phyllodes tumor cell strain, a filial generation cell line thereof, and use thereof. The cell line is named malignant human breast phyllodes tumor cell line SYSH-MPT-04, and is deposited under CCTCC NO. C2022190 ...
|
|
WO/2024/052485A1 |
The invention is based on the use of mitophagy agonists as defined in the claims, in particular Urolithin A, for improving mitochondrial health in immune cells such as T-cells. The invention provides new strategies to enhance immune cell...
|
|
WO/2024/049158A1 |
The objective of the present invention is to provide a method for effectively isolating and proliferating stem cells from the peripheral blood. A composition according to the present invention comprises interferon-gamma (IFN-γ) so as to...
|
|
WO/2024/046239A1 |
The present invention relates to a specific recombinant humanized monoclonal antibody targeting human GPRC5D and an application thereof, can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeti...
|
|
WO/2024/046329A1 |
Provided is a composition including stem cell is derived from amniotic fluid of an artiodactyl animal. Also provided relates to uses of the composition for skin rejuvenation, skin treatment, promoting hair growth, and preventing hair los...
|
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/048899A1 |
The present invention relates to a pharmaceutical composition for alleviating or treating sequelae of cerebral infarction, comprising glia-like cells differentiated from a human mesenchymal stem cell (hMSC). The pharmaceutical compositio...
|
|
WO/2024/048418A1 |
Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1. The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ES...
|
|
WO/2024/046072A1 |
Disclosed are an immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof. Specifically, disclosed are mbIL-21 and a use thereof in immunotherapy. mbIL-21 can enhance the expansion capability...
|
|
WO/2024/050517A1 |
This invention relates to methods of producing reprogrammed B cells, methods of treating cancer, and methods of enhancing an immune response in a subject having, suspected to have and/or at risk of cancer. The invention further relates t...
|
|
WO/2023/026194A9 |
The present disclosure is directed to a novel sequence constructed from viral elements for use as a transgenic promoter; for example, in transgenic plants. More specifically, the present disclosure is directed to a chimeric transgenic pr...
|
|
WO/2024/046384A1 |
The present invention relates to an antibody specifically binding to a TSHR or an antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a nucleic acid molecule enc...
|
|
WO/2024/050399A1 |
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-do...
|
|
WO/2024/050546A1 |
Disclosed herein include methods, compositions and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells such as pluripotent embryonic stem cells. In some embodiments, the method can comprise co-cu...
|
|
WO/2024/046355A1 |
Use of a composition including mesenchymal stem cells in the manufacture of a medicament for alleviating myelofibrosis in a subject is provided.
|
|
WO/2024/048731A1 |
Naïve pluripotent stem cells are produced at high efficiency. A method for producing naïve pluripotent stem cells, wherein the method includes the following steps: (1) a step that cultures primed pluripotent stem cells in primed pl...
|
|
WO/2024/045890A1 |
The present invention provides a preparation method for dendritic cell progenitors and a culture medium thereof, and particularly provides a method for preparing dendritic cell progenitors, comprising the step of: culturing cells from pe...
|
|
WO/2024/049713A1 |
Improved nerve regeneration scaffolds are disclosed, which include a plurality of modified nanotube yarn bundles disposed of within the scaffold lumen. The modified nanotube yarn bundles have enhanced hydrophilicity and water absorption....
|
|
WO/2024/047110A1 |
The present invention relates to a new method to obtain more effective CAR-T cells. Here, the inventors worked on the function of FOXO1 in T lymphocyte physiology for many years. They recently described, using a FOXO1 pharmacological inh...
|
|
WO/2024/049658A1 |
A method for functionalizing a hollow-fiber membrane for cell expansion of targeted cells (e.g., natural killer cells) includes contacting a biotinylating molecule to a surface of the hollow-fiber membrane including an extracellular matr...
|
|
WO/2024/050534A2 |
Disclosed are CD34+ hematopoietic stem progenitor cells (HSPCs) generated from induced pluripotent stem cells (iPSCs) and T cells generated from iPSCs under minimal cytokine conditions, and methods of generating and using the same for th...
|
|
WO/2024/045404A1 |
Provided are a bone marrow supernatant and use thereof in stem cell culture. The bone marrow supernatant is obtained by means of treating a bone marrow sample of a newborn mammal, is used as a culture medium additive for cell culture, ca...
|
|
WO/2024/050555A1 |
Disclosed herein include methods and compositions for use in generating synthetic embryos. In some embodiments, the method comprises culturing stem cells that over-express at least one Cadherin.
|
|
WO/2024/044852A1 |
Described herein is a high-throughput method of synthesizing biofunctional microparticles. In aspects, the method comprises casting biofunctional microparticle precursors onto a microporous template to form microparticles, wherein the te...
|
|
WO/2024/048079A1 |
Provided are: a method for predicting, at high accuracy and low cost, the production stability of a clone that produces a useful substance; an information processing device; a program; and a prediction model generation method. According ...
|
|
WO/2024/046394A1 |
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an im...
|
|
WO/2024/048050A1 |
According to the present disclosure, provided is a carrier peptide fragment having excellent cell membrane permeability. The disclosed carrier peptide fragment comprises an amino acid sequence represented by SEQ ID NO: 1, KKRTLRKSNRKKR, ...
|
|
WO/2024/046393A1 |
Provided is a method for trans-differentiating non-neuronal cells of a mammal into neurons. The method comprises: providing a negative regulator capable of reducing the expression of negative regulatory genes, the negative regulatory gen...
|
|
WO/2024/050497A2 |
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable...
|
|
WO/2024/048900A1 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular dementia comprising glia-like cells differentiated from human mesenchymal stem cells (hMSC). The pharmaceutical composition of the present ...
|
|
WO/2024/046032A1 |
The present invention relates to ionic liquids based on non-natural amino acids, a preparation method therefor, and use thereof, and particularly provides a substance combination for preparing a protein containing non-natural amino acids...
|
|
WO/2024/048643A1 |
The purpose of the present invention is to provide an exosome production method which makes it possible to produce an exosome with high efficiency. The exosome production method comprises: a step for culturing a cell (12) using a cell fi...
|
|
WO/2024/046245A1 |
Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression o...
|
|
WO/2024/048334A1 |
This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequenc...
|
|
WO/2024/047368A1 |
This invention relates to expanded Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to increasing the number of CD16+ NK cells within ex...
|
